BioteQ Releases Results for Q1 2013

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 13, 2013) - BioteQ Environmental Technologies Inc. (TSX:BQE), a leader in industrial waste water treatment, releases its financial and operating results for the first quarter ended March 31, 2013. Further information on the first quarter results can be obtained from the Company's Unaudited Condensed Consolidated Interim Financial Statements and Management's Discussion and Analysis ("MD&A").

BioteQ will hold a conference call on May 14, 2013 at 11:00 AM EDT to discuss results for Q1 2013. Participants can dial in at 416-695-7806 or 888-789-9572; participant pass code 3207139. European callers can dial in at 800-4222-8835; participant pass code 3207139.

Due to recent changes in Generally Accepted Accounting Standards ("GAAP") effective Q1 2013, the results of the Company's joint ventures will be accounted for as equity investments in BioteQ's current and future financial statements. In prior years, the results of the Company's joint ventures were accounted for through proportionate consolidation. Going forward, the revenue and operating costs associated with the Company's proportionate share of activities in joint ventures will be netted and disclosed as a single line item on the Consolidated Statements of Operations and the Company's share of assets, liabilities and equity in each joint venture will be presented as a net investment on the Consolidated Statement of Financial Position. The change in accounting standard will not impact overall, consolidated profitability or cash flow in past or future periods. However this change will, given the mandated accounting treatment, result in the Company showing lower revenues than has historically been the case.

To ensure clarity and comparability with historic results, certain statements in this news release and in the MD&A are characterized as BioteQ's "proportional" share, which means the effective portion of results that BioteQ would have reported if each of its joint ventures had been reported in accordance with past accounting standards. For further details, please see "Non-GAAP Measures" in the Company's Q1 2013 MD&A.

Q1 2013 Financial and Operations results

BioteQ's results for Q1 2013 were in line with the company's expectations:

Financial

• Proportional revenue for Q1 2013 was $1.94 million compared to $2.16 million in Q1 2012. The slight decline in revenue compared to the prior year was due to the fact that the sale of a mobile water treatment plant for approximately $1 million was recognized in Q1 in 2012. During Q1 2013, this sale was largely offset by increased copper recovery at the Dexing plant, increased revenue for services provided to Kinross at a gold mine site, and increased laboratory and pilot testing activities.
• Proportional gross margins for Q1 2013, which include BioteQ's share of joint venture activities, were $552,000 compared to $756,000 in Q1 2012. Lower overall margins were, in part, driven by lower operating margins at the Dexing site. We expect that operating margins at Dexing will return to normal levels during Q2 and Q3.
• Revenue as reported under the GAAP equity method was $796,000 in Q1 2013 compared to $1.38 million in Q1 2012.
• Gross margins for the quarter as reported under GAAP were $188,000 in Q1 2013 compared to $420,000 in 2012. Lower margins were the result of a change in the sales mix from a higher margin plant sale in Q1 2012 to lab and pilot testing activities in the relevant period that generated relatively lower gross margins.
• Net loss for the quarter was $1.0 million in Q1 2013 compared to a loss of $989,000 in Q1 2012.
• Comprehensive net loss for Q1 2013 was $866,000 compared to 1.1 million in Q1 2012.
• Adjusted EBITDA for the quarter was ($755,000), similar to adjusted EBITDA of ($749,000) in Q1 2012.
• Total cash and short term investments, including BioteQ's share of cash held in joint ventures, was $6.1 million compared to $7.5 million at the end of 2012. The decline in cash was largely due to working capital requirements during the quarter.

Operational

• The Bisbee, Arizona operation recovered approximately 140,000 pounds of copper and treated 290,000 cubic metres of water during the first quarter. In Q1 2012, the plant recovered 160,000 pounds of copper and treated 310,000 cubic metres of water. The operation is expected to recover approximately 600,000 pounds of copper during the year.
• The Dexing, China operation recovered approximately 511,000 pounds of copper and treated 2.2 million cubic metres of water during the first quarter. In Q1 2012, the plant recovered 373,000 pounds of copper and treated 1.5 million cubic metres of water. The operation is expected to recover approximately 1.8 million pounds of copper during the year.
• BioteQ is currently in the process of constructing and commissioning two plants at the Dexing mine site in China with its joint venture partner, Jiangxi Copper Company ("JCC"):
  • A nickel/cobalt recovery ion exchange plant is in the final stages of technical modifications and is expected to begin commissioning in the second half of Q2 2013. Commissioning should be completed in early Q3 2013. We expect the plant will ramp up to full commercial production during that quarter.
  • Progress on the construction of a second copper recovery plant at the site, announced in late 2012, has experienced minor delays with site preparation work due to weather conditions at the site. Site preparation work has now been completed and design and procurement activities continue to progress. The new plant is expected to be completed and to start up in Q4 2013.
    Collectively these two plants are expected to add modestly to revenue in 2013 but are expected to contribute approximately an additional $1.5-2.0 million in BioteQ's proportional recurring revenues in 2014.
• During Q1 2013, we successfully completed commissioning and initial field piloting of a mobile Sulf-IX™ pilot plant that was jointly funded by Newalta and BioteQ. This unit provides on-site field testing for sulphate removal from waste water.
  Subsequent to Q1 2013, BioteQ announced the sale of its ownership share of the mobile Sulf-IX™ pilot plant to Newalta for approximately $500,000 Cdn. Under the terms of the agreement, BioteQ will continue to retain full ownership of its Sulf-IX™ intellectual property. However, sale of this test unit will ensure that planning and execution for deployment of the unit will be more efficient and that the new arrangement will more effectively leverage the strengths of both Newalta and BioteQ on future test campaigns. For financial reporting purposes, the sale of this unit to Newalta will be accounted for as a disposal of a fixed asset.
• During the quarter, BioteQ continued to advance a number of testing and pilot opportunities and devoted significant efforts to further developing our sales pipeline.
• Litigation with Aditya Birla Minerals ("Birla") remains in progress. Both parties have now submitted initial discovery to the court. We have reviewed all materials and have requested additional materials be provided by Birla. We expect that in May the court will determine the next steps in the litigation process. At present we expect the dispute will proceed to conclusion in 2013. BioteQ continues to believe that Birla's claims are without merit. BioteQ intends to continue to vigorously defend its position and to pursue its claim for damages.

Outlook

Earlier in 2013 BioteQ provided a financial and operational outlook for 2013. Our 2013 targets were stated as follows:

• Proportional Revenue: BioteQ is targeting to grow revenue in 2013, on a proportionate revenue basis, by 25% over 2012 to approximately $11.8 million (between $5.5 and $6.5 million on a GAAP equity accounting basis). Proportional Revenue growth is expected to be generated from: the completion of plants currently under construction at the Dexing site; large scale piloting campaigns with customers in North and South America; plant sales; and engineering and technical development projects.
• Adjusted EBITDA: BioteQ is targeting to improve its adjusted EBITDA by approximately 50% to less than ($1) million from ($1.9) million in 2012. The projected improvement in adjusted EBITDA is expected to come from additional margin generated from increased sales revenues and from continued improvements in the efficiency of our operating and engineering activities.

While BioteQ's adjusted EBITDA loss was approximately $755,000 in Q1 2013, the Company anticipates stronger bottom line performance over the coming three quarters as the Raglan plant commences operations and as BioteQ recognizes additional revenues from field piloting and laboratory contracts, and from other sales opportunities.

BioteQ remains optimistic with regard to prospects for 2013 and beyond. As a result, 2013 targets for Proportional Revenue growth and adjusted EBITDA remain unchanged.

It should be noted however that a significant portion of BioteQ's Proportional Revenues and profitability remain tied to copper prices. In recent months, the price of copper has fallen and been quite volatile. At the beginning of the year, copper prices were approximately USD $3.65/pound on the London Metals Exchange (LME). Currently, they are approximately USD $3.30/pound on the LME. A sustained decline in copper prices could have a material impact on Proportional Revenue and adjusted EBITDA forecast for the year.

BioteQ Corporate Profile

BioteQ is an innovative clean technology leader in global industrial water treatment, serving the mining and energy markets. The company's proven technologies have been applied at sites around the world to recover dissolved metals and remove sulphate, producing clean water and eliminating residual waste. BioteQ is headquartered in Vancouver, Canada and trades on the TSX under the symbol BQE. Please visit our website at www.bioteq.ca for additional information.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain information contained herein may not be based on historical fact and therefore constitutes "forward-looking information" under applicable Canadian securities legislation. This includes without limitation statements containing the words "plan", "expect", "project", "estimate", "intend", "believe", "anticipate", "may", "will" and other similar words or expressions. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's dependence on key personnel and contracts, uncertainty with respect to the profitability of the Company's technologies, competition, technology risk, the Company's ability to protect its intellectual property and proprietary information, fluctuations in commodity prices, currency risk, environmental regulation and the Company's ability to manage growth and other factors described in the Company's filings with the Canadian securities regulators at www.sedar.com (including without limitation the factors described in the section entitled "Risks and Uncertainties" in the Company's Annual Report for the year ended December 31, 2012 and the section entitled "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2012). Given these risks and uncertainties, the reader is cautioned not to place undue reliance on forward-looking statements. All forward-looking information contained herein is based on management's current expectations and the Company undertakes no obligation to revise or update such forward-looking information to reflect subsequent events or circumstances, except as required by law.

BioteQ Environmental Technologies Inc.
Consolidated Interim Statement of Financial Position
(Unaudited)

	Mar 31 2013	Dec 31 2012
	$	$
		(note 21 and 24)
Assets
Current assets
Cash and cash equivalents	1,014,702	2,412,892
Restricted cash (note 5)	71,848	-
Short-term investments	1,075,871	1,455,472
Trade receivables	1,359,172	1,075,141
Receivable from joint venture partners	104,936	198,634
Taxes recoverable	1,272	886
Inventory (note 6)	22,788	22,788
Work in progress	133,682	229,797
Asset held for sale (note 7)	425,997	-
Other receivable and prepaid expenses (note 12)	462,620	221,873
	4,672,888	5,617,483
Non-current assets
Property, plant and equipment (note 9 and 16)	759,476	1,274,966
Intangible asset	30,967	38,710
Investment in Bisbee joint venture (note 8 and 21)	1,490,167	1,501,577
Investment in Dexing joint venture (note 8 and 21)	6,505,280	6,145,293
Total assets	13,458,778	14,578,029
Liabilities
Current liabilities
Accounts payable and accrued liabilities	1,034,278	1,342,707
Deferred revenue	129,070	91,970
Taxes payable	252,229	251,930
Deferred lease inducement	51,434	60,090
	1,467,011	1,746,697
Non-current liabilities
Long-term liabilities (note 10)	76,243	84,723
Total liabilities	1,543,254	1,831,420
Shareholders' Equity
Capital stock and warrants (note 11)	55,269,416	55,269,416
Contributed surplus	8,281,670	8,247,007
Accumulated other comprehensive loss	(950,254)	(1,097,611)
Deficit	(50,685,308)	(49,672,203)
Total shareholders' equity	11,915,524	12,746,609
Total liabilities and shareholders' equity	13,458,778	14,578,029

Commitments (note 19)
Contingency (note 23)

For a complete set of Financial Statements, please go to www.bioteq.ca.

BioteQ Environmental Technologies Inc.
Consolidated Interim Statements of Operations and Comprehensive Loss
For the three months ended March 31, 2013 and 2012
(Unaudited)

		3 months ended Mar 31,
		2013	2012
		$	$
			(note 21 and 24)
Revenue		796,241	1,378,943
Plant and other operating costs (not including depreciation)		607,862	958,970
		188,379	419,973
	General and administration	970,393	1,092,777
	Sales and development	474,172	311,933
	Stock-based compensation (note 11)	34,663	21,551
	Depreciation of property, plant and equipment (note 9)	138,023	116,170
	Amortization of intangible asset	7,743	7,743
Loss before the under-noted		(1,436,615)	(1,130,201)
	Interest income	5,266	12,965
	Foreign exchange gain	87,807	67,842
	Reversal of impairment of Lluvia de Oro operations (note 12)	200,000	-
	Share of results of equity accounted joint ventures (note 8 and 21)	132,592	61,021
Loss before income taxes		(1,010,950)	(988,373)
	Income taxes (note 14)	2,156	-
Net loss for the period		(1,013,106)	(988,373)
Other comprehensive income (loss)
	Cumulative translation adjustment	147,357	(73,362)
Comprehensive loss for the period		(865,749)	(1,061,735)
Net loss per share
Basic and diluted		(0.01)	(0.01)
Weighted average number of shares outstanding
Basic and diluted		69,966,672	69,966,672

For a complete set of Financial Statements, please go to www.bioteq.ca.

BioteQ Environmental Technologies Inc.
Consolidated Interim Statement of Changes in Equity
For the three months ended March 31, 2013 and 2012
(Unaudited)

	Number of shares	Capital stock	Warrants	Contributed Surplus	Accumulated other comprehensive income (loss)	Deficit	Total
	#	$	$	$	$	$	$
Balance - January 1, 2012	69,966,672	53,755,999	1,513,417	8,117,400	(1,075,369)	(46,305,460)	16,005,987
Stock-based compensation (note 11)	-	-	-	21,551	-	-	21,551
Net loss for the year	-	-	-	-	-	(988,373)	(988,373)
Other comprehensive loss for the period	-	-	-	-	(73,362)	-	(73,362)
Balance - March 31, 2012	69,966,672	53,755,999	1,513,417	8,138,951	(1,148,731)	(47,293,833)	14,965,803
Balance - January 1, 2013	69,966,672	53,755,999	1,513,417	8,247,007	(1,097,611)	(49,672,203)	12,746,609
Stock-based compensation (note 11)	-	-	-	34,664	-	-	34,664
Net loss for the period	-	-	-	-	-	(1,013,106)	(1,013,106)
Other comprehensive income for the period	-	-	-	-	147,357	-	147,357
Balance - March 31, 2013	69,966,672	53,755,999	1,513,417	8,281,671	(950,254)	(50,685,309)	11,915,524

For a complete set of Financial Statements, please go to www.bioteq.ca.

BioteQ Environmental Technologies Inc.
Consolidated Interim Statement of Cash Flows
For the three months ended March 31, 2013 and 2012
(Unaudited)

		3 months ended Mar 31,
		2013	2012
		$	$
			(note 21 and 24)
Cash flow used in
Operating activities
Net loss for the period		(1,013,106)	(988,373)
Items not affecting cash:
	Depreciation of property, plant and equipment	138,023	116,170
	Amortization of intangible asset	7,743	7,743
	Amortization of deferred lease inducement	(2,857)	(7,105)
	Share of results of equity accounted joint ventures	(132,592)	(61,021)
	Unrealized foreign exchange loss (gain)	115,454	(138,533)
	Interest income	(5,289)	(8,208)
	Stock-based compensation charge (note 11)	34,663	21,551
		(857,961)	(1,057,776)
Change in non-cash working capital items (note 15)		(606,382)	(39,725)
Net cash used in operating activities		(1,464,343)	(1,097,501)
Investing activities
Purchase of property, plant and equipment		(48,710)	(84,921)
Net distributions received from (contributions to) joint ventures		(215,985)	18,217
Purchase of short-term investments		(997,110)	4,048,860
Proceeds from sale of short-term investments		1,382,000	-
Net cash provided by (used in) investing activities		120,195	3,982,156
Financing activities
Increase in restricted cash		(71,848)	-
Decrease in deferred lease inducement		(5,799)	-
Net cash used in financing activities		(77,647)	-
		(1,421,794)	2,884,655
Effect of exchange rate changes on cash		23,604	52,864
Increase in cash		(1,398,190)	2,937,519
Cash
	Beginning of period	2,412,892	2,675,858
	End of period	1,014,702	5,613,377

For a complete set of Financial Statements, please go to www.bioteq.ca.